Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Deutsche Boerse AG  >  UCB SA    UNC   BE0003739530

UCB SA (UNC)

Delayed Quote. Delayed  - 04/27 08:02:19 am
72.423 EUR   +2.58%
06:12p UCB : General Meeting of Shareholders
04/26 UCB : receives positive CHMP opinion for CIMZIA® (certolizumab pegol..
04/24 UCB FIRST THREE :  UCB with …
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Deutsche Boerse Ag
04/21/2017 04/24/2017 04/25/2017 04/26/2017 04/27/2017 Date
72.357(c) 72.215(c) 70.215(c) 70.604(c) 72.423 Last
0 0 0 0 0 Volume
+0.87% -0.20% -2.77% +0.55% +2.58% Change
More quotes
Financials (€)
Sales 2017 4 282 M
EBIT 2017 934 M
Net income 2017 597 M
Debt 2017 551 M
Yield 2017 1,65%
Sales 2018 4 537 M
EBIT 2018 1 102 M
Net income 2018 728 M
Finance 2018 22,5 M
Yield 2018 1,78%
P/E ratio 2017 21,87
P/E ratio 2018 18,05
EV / Sales2017 3,44x
EV / Sales2018 3,12x
Capitalization 14 181 M
More Financials
Company
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products.It offers medicinal products for central nervous system and immunology disorders under the Cimzia, Xyzal, Zyrtec, Tussionex, Lortab, Vimpat, Keppra and Neupro.The company was founded by... 
Sector
Pharmaceuticals
Calendar
04/27Shareholder meeting
More about the company
Surperformance© ratings of UCB SA
Trading Rating : Investor Rating :
More Ratings
Latest news on UCB SA
06:12p UCB : General Meeting of Shareholders
04/26 UCB : receives positive CHMP opinion for CIMZIA® (certolizumab pegol) dose &hell..
04/24 UCB FIRST THREE MONTHS INTERIM REPOR :  UCB with …
04/20 UCB : Findings from UCB S.A. Provides New Data on Epilepsy (Health care cost ass..
04/19UCB SA : quaterly earnings release
04/10 UCB : U.S. Patent and Trademark Office confirms validity of patent …
04/10 UCB : Acquisition of own shares
04/07 UCB : Acquisition of own shares
04/04 UCB : and Q-State Biosciences Form Research Collaboration …
04/03 AMGEN : Ucb and amgen report new data at endo 2017 examining the option of a sec..
More news
Sector news : Pharmaceuticals - NEC
10:10aDJASTRAZENECA : Profit Drops on Decline in Blockbuster-Drug Revenue -- Update
09:41aDJASTRAZENECA : Correction to AstraZeneca Profit Drops on Decline in Blockbuster-D..
09:26aDJBAYER : First-Quarter Net Profit Up 38% at EUR2.08 Billion -- Update
08:48aDJGLAXOSMITHKLINE : New Glaxo CEO Seeks Tighter Drug Focus -- WSJ
08:45aDJASTRAZENECA : Profit Drops on Decline in Blockbuster-Drug Revenue
More sector news : Pharmaceuticals - NEC
Advertisement
Chart UCB SA
Duration : Period :
UCB SA Technical Analysis Chart | UNC | BE0003739530 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 17
Average target price 75,4 €
Spread / Average Target 3,4%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Gerhard N. Mayr Chairman
Mark D. McDade Chief Operating Officer & Executive Vice President
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Löw-Friedrich Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
UCB SA15.04%15 457
JOHNSON & JOHNSON7.20%334 822
ROCHE HOLDING LTD.10.83%223 653
PFIZER INC.3.94%201 581
NOVARTIS AG2.77%201 384
MERCK & CO., INC.6.51%171 894
More Results